Breaking News

3P Bio and Toleranzia Enter Orphan Drug Partnership

Hope for a new treatment for the autoimmune neuromuscular disease Myasthenia Gravis, drug candidate TOL2 has achieved several positive preclinical results.

By: Contract Pharma

Contract Pharma Staff

3P Biopharmaceuticals, contract development and manufacturing organization (CDMO) specialized in process development and cGMP manufacturing of biologics, together with Toleranzia, a Swedish biotech company, have initiated a collaboration for an innovative treatment for the autoimmune neuromuscular disease Myasthenia Gravis (MG). 3P Biopharmaceuticals and Toleranzia began their partnership in 2019, when 3P Biopharmaceuticals was selected to be responsible for the cell line, process and analytica...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters